Kidney Week

Abstract: SA-PO0906

Effect of Intradialytic Parenteral Nutrition on Lean Tissue Mass in Patients on Hemodialysis: Results of a Double-Blind, Placebo-Controlled Randomized Trial

Session Information

• Health Maintenance, Nutrition, and Metabolism
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Health Maintenance, Nutrition, and Metabolism

• 1500 Health Maintenance, Nutrition, and Metabolism

Authors

• Geus, Manon De, Department of Internal Medicine, Division of Dietetics, Erasmus MC, University Medical Center, Rotterdam, Netherlands

Manon De Geus, MSc, RD

• Paijmans, Amber, Department of Internal Medicine, Division of Dietetics, Erasmus MC, University Medical Center, Rotterdam, Netherlands

Amber Paijmans

• de Mik - van Egmond, Anneke, Department of Internal Medicine, Division of Dietetics, Erasmus MC, University Medical Center, Rotterdam, Netherlands

Anneke de Mik - van Egmond

• Verhoeven, Martine, Franciscus Gasthuis en Vlietland, Rotterdam, ZH, Netherlands

Martine Verhoeven, MD

• Nette, Robert, Franciscus Gasthuis en Vlietland, Rotterdam, ZH, Netherlands

Robert Nette, MD, PhD

• Hoorn, Ewout J., Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands

Ewout J. Hoorn, MD, PhD

• Severs, David, Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands

David Severs, MD

• Visser, Wesley, Department of Internal Medicine, Division of Dietetics, Erasmus MC, University Medical Center, Rotterdam, Netherlands

Wesley Visser, PhD

Background

Progressive loss of lean tissue mass (LTM) is common in hemodialysis (HD) patients and is associated with adverse clinical outcomes. Intradialytic parenteral nutrition (IDPN) may counteract this, but evidence from randomized trials evaluating body composition, muscle strength, and quality of life is limited.

Methods

In this two-center, double-blind, placebo-controlled randomized trial, adult HD patients were randomized 1:1 to receive either IDPN (1000 mL Olimel N12; 950 kcal, 75.9 g amino acid) or placebo (1000 mL 5% glucose; 200 kcal) during each dialysis session for 12 weeks. The primary outcome was change in LTM assessed by bioelectrical impedance spectroscopy. Secondary outcomes included handgrip strength and health-related quality of life (Kidney Disease Quality of Life [KDQOL] Short Form). Based on the predefined effect size, a total sample size of 166 patients was planned. Longitudinal between-group changes were analyzed using linear mixed models (intention-to-treat analysis).

Results

Ninety-two of the planned 166 patients were randomized; 20 discontinued within 2 weeks, leaving 72 for analysis. The number of administered infusions was lower and more variable in the IDPN group than in the placebo group (29 [IQR 11–34] vs. 33 [27–35]). Participants were predominantly male (68%), with a median age of 65 years, dialysis vintage of 10 months, and a high Charlson Comorbidity index of 7. At baseline, 51% of participants had a low lean tissue index (<P10) and 38% of participants had a low handgrip strength (<P10). After 12 weeks, no between‑group difference was observed for LTM (0.008 (= 0.63 kg); 95% CI −0.03 to 0.05; P=0.69) or handgrip strength (−0.87 kg; 95% CI −3.12 to 1.38; P=0.46). Likewise, scores did not differ for the KDQOL Energy domain (−0.75 points; 95% CI −8.27 to 6.77; P=0.84), although a non‑significant trend toward improvement in the KDQOL Health domain was observed in the IDPN group (5.38 points; 95% CI −0.54 to 11.30; P=0.07).

Conclusion

Twelve weeks of IDPN did not improve LTM, muscle strength, or quality of life in HD patients.

Funding

• Commercial Support – Baxter B.V.